Breast Cancer Research and Treatment

, Volume 53, Issue 1, pp 33–39 | Cite as

Analyses of microsatellite instability and the transforming growth factor‐β receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features

  • Shuji Tomita
  • Shigeru Deguchi
  • Takao Miyaguni
  • Yoshihiro Muto
  • Tohru Tamamoto
  • Takayoshi Toda


To determine the incidence of microsatellite instability (MSI) and its relationship with both clinicopathologic parameters and patient survival, 101 cases of breast cancer were investigated. In addition, transforming growth factor‐β (TGF‐β) receptor type II (RII) gene mutation was also examined to clarify the relation to MSI in breast cancer development. MSI and RII gene mutation were screened by single strand conformation polymorphism (SSCP). The mutations of the RII gene were confirmed by a direct sequence. An association between the MSI status and the clinicopathological features was examined to assess the potential of the MSI status as a prognostic indicator in sporadic breast cancer cases. MSI was detected in 12 of 101 (11.9%) breast cancer cases. The positive MSI breast cancer cases showed relatively more advanced disease than negative MSI cases, and also exhibited relatively poorer prognoses. No RII gene mutations were observed in any of the breast cancer cases. Our data suggest that the MSI status may thus be a useful indicator for the prognosis of sporadic breast cancer cases. However, the breast seems to be an infrequent target organ for cancer development through RII gene mutations. As a result, tumor progression through this pathway appears to be related to organ specificity. For positive MSI breast cancers, other target genes therefore still need to be identified.

breast cancer microsatellite instability TGF‐β RII gene clinicopathological features prognosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260: 816–819, 1993Google Scholar
  2. 2.
    Aaltonen LA, Peltomaki P, Leach F, Sistonen P, Pylkkanen L, Mecklin J-P, Jarvinen H, Powell MS, Jen J, Hamilton RS, Petersen MG, Kinzler WK, Vogelstein B, Chapelle A: Clues to the pathogenesis of familial colorectal cancer. Science 260: 812–816, 1993Google Scholar
  3. 3.
    Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch H, Boyd J: Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53: 5100–5103, 1993Google Scholar
  4. 4.
    Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Lahti NM, Seruca R, David L, Holm R, Ryberg D, Haugen A, Brogger A, Borresen A-L, Chapelle A.: Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53: 5853–5855, 1993Google Scholar
  5. 5.
    Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO, Fossa SD, Haldorsen T, Langmark F, Brogger A, de la Chapelle A, Borresen A-L: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53: 5849–5852, 1993Google Scholar
  6. 6.
    Honchel R, Halling KC, Schaid DJ, Pittelkow M, Thibodeau SN: Microsatellite instability in Muir-Torre syndrome. Cancer Res 54: 1159–1163, 1994Google Scholar
  7. 7.
    Risio M, Reato G, Celle PF, Fizzotti M, Rossini FP, Foa R: Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer. Cancer Res 56: 5470–5474, 1996Google Scholar
  8. 8.
    Seruca R, Santos NR, David L, Constancia M, Barroca H, Carneiro F, Seixas M, Peltomaki P, Lothe R, Sobrinho-Simoes M: Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. Int J Cancer 64: 32–36, 1995Google Scholar
  9. 9.
    Paulson TG, Wright FA, Parker BA, Russack V, Wahl GM: Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 56:4021–4026, 1996Google Scholar
  10. 10.
    Wrana JL, Attisano L, Weiser R, Ventura F, Massague J: Mechanism of activation of the TGF-breceptor. Nature 370:341–347, 1994Google Scholar
  11. 11.
    Alexandrow MG, Moses HL: Transforming growth factor-b and cell cycle regulation. Cancer Res 55: 1452–1457, 1995Google Scholar
  12. 12.
    Massague J: The transforming growth factor-bfamily. Annu Rev Cell Biol 6: 597–641, 1990Google Scholar
  13. 13.
    MacKay SLD, Yaswen LR, Tarnuzzer RW, Moldawer LL, Bland KI, Copeland EM, Schultz GS: Genetic changes in the transforming growth factor b (TGF-b) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-b. Ann Surg 221: 767–777, 1995Google Scholar
  14. 14.
    Filmus J, Kerbel RK: Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-b during tumor progression. Opin Oncol 5:123–129, 1993Google Scholar
  15. 15.
    Geiser AG, Burmester JK, Webbink R, Roberts BA, Sporn BM: Inhibition of growth by transforming growth factor-b following fusion of two nonresponsive human carcinoma cell lines. J Biol Chem 267: 2588–2593, 1992Google Scholar
  16. 16.
    Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF, Brattain MG: Expression of transforming growth factor b type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269: 26449–26455, 1994Google Scholar
  17. 17.
    Park K, Kim SJ, Bang Y, Park JG, Kim NK, Roberts AB, Sporn MB: Colon cancer cells that are not growth inhibited by TGF-b lack functional type I and type II TGF-b receptors. Proc Natl Acad Sci 91: 8772–8776, 1994Google Scholar
  18. 18.
    Markowitz S, Wang J, Myeroff L, Persons R, Sun L, Lutterbaugh J, Fan SR, Zborowska E, Kinzler WK, Vogelstein B, Brattain M, Willson KVJ: Inactivation of the type II TGF-b receptor in colon cancer cells with microsatellite instability. Science 268: 1336–1338, 1994Google Scholar
  19. 19.
    Lu SL, Akiyama Y, Nagasaki H, Saitoh K, Yuasa Y: Mutations of the transforming growth factor-b type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem Biophys Res Commun 216:452–457, 1995Google Scholar
  20. 20.
    Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Microsatellite instability and mutations of the transforming growth factor-b type II receptor gene in colorectal cancer. Cancer Res 55: 5548–5550, 1995Google Scholar
  21. 21.
    Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K: A transforming growth factor b receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55: 5545–5547. 1995Google Scholar
  22. 22.
    Vincent F, Hagiwara K, Ke Y, Stoner DG, Demetrick JD, Bennett PW: Mutation analysis of the transforming growth factor b type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem Biophys Res Commun 223: 561–564, 1996Google Scholar
  23. 23.
    Hori H, Miyake S, Akiyama Y: Clonal heterogeneity in human esophageal squamous cell carcinomas on DNA analysis. Jpn J Cancer Res 87: 923–929, 1996Google Scholar
  24. 24.
    Togo G, Toda N, Kanai F, Kato N, Shiratori Y, Kishi K, Imazeki F, Makuuchi M, Omata M: A transforming growth factor b type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res 56:5620–5623, 1996Google Scholar
  25. 25.
    Martinsson T, Sjoberg RM, Hedborg F, Kogner P: Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short tandem repeat polymorphisms. Cancer Res 55: 5681–5686, 1995Google Scholar
  26. 26.
    Yee CJ, Roodi N, Verrier CS, Parl FF: Microsatellite instability and loss of heterozygosity in breast cancer. Cancer Res 54: 1641–1644, 1994Google Scholar
  27. 27.
    Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M: Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55: 3976–3981, 1995Google Scholar
  28. 28.
    Ji H, Stout LE, Zhang Q, Zhang R, Leung HT, Leung BS: Absence of transforming growth factor-b responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1. J Cell Biochem 54: 332–342, 1994Google Scholar
  29. 29.
    Kalkhoven E, Beraldi E, Panno ML, De Winter JP, Thijssen JHH, Van Der Burg B: Growth inhibition by antiestrogens and progestins in TGF-b-resistant and-sensitive breast-tumor cells. Int J Cancer 65: 682–687, 1996Google Scholar
  30. 30.
    Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL: Blockade of transforming growth factor-b signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J Biol Chem 272: 8296–8302, 1997Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Shuji Tomita
    • 1
  • Shigeru Deguchi
    • 1
  • Takao Miyaguni
    • 1
  • Yoshihiro Muto
    • 1
  • Tohru Tamamoto
    • 2
  • Takayoshi Toda
    • 2
  1. 1.First Department of SurgeryJapan
  2. 2.Department of Laboratory Medicine, School of MedicineUniversity of the RyukyusOkinawaJapan

Personalised recommendations